

Press Release |

IBA AND HAE DONG JOIN FORCES TO GROW MARKET FOR PET RADIOPHARMACEUTICALS IN SOUTH KOREA

For Immediate Release – September 25, 2008

Louvain-la-Neuve, Belgium and Seoul, South Korea, September 25, 2008 – IBA (Ion Beam Applications S.A.) and Hae Dong Co. Ltd., announced today that they are joining forces to grow the market for PET (Positron Emission Tomography) Radiopharmaceuticals in South Korea.

The Memorandum of Understanding signed today calls for IBA to support Hae Dong in its efforts to educate the Nuclear Medicine and associated Physician community on the benefits of PET imaging for approved indications. IBA confirmed Hae Dong will be its preferred partner in South Korea for the distribution of PET Radiopharmaceuticals exclusively licensed by IBA, and its preferred technology partner for PET Radiopharmaceuticals.

The addition of Hae Dong's 7 FDG production centers (5 operational and 2 under construction) in South Korea means that IBA's PET Radiopharmaceuticals production and distribution network now includes a total of 45 facilities worldwide.

"We are pleased about this strategic partnership with Hae Dong, a leader in the PET radiopharmaceuticals distribution market in South Korea", said Pierre Mottet, Chief Executive Officer of IBA. "We are already the leading supplier of PET Radiopharmaceuticals worldwide and this partnership further strengthens our presence in Asia. We very much look forward to our enhanced cooperation", continued Mr. Mottet.

"We are pleased to strengthen our partnership with IBA in Korea. With this partnership we will have access to world class technology solutions developed by IBA and this will enable us to increase our leadership in the Korean market ", said Mr. S.J. Jung, President of Hae Dong Co. Ltd.

ABOUT HAE DONG CO. LTD.

Haedong was established in 1982 and is a leader in the Korean market for Radiation Oncology products and Nuclear Medicine. Haedong's key strength lies in providing Total Solution to its customers including turnkey solutions and financing options to suit customer's needs. With 5 FDG production centres and 2 more being installed, Haedong has a clear leadership in the radiopharmaceuticals distribution business in Korea.



海東器機株式會社
Hae Dong Co., Ltd.



Press Release |

ABOUT IBA

IBA develops and markets leading edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization. Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index.

(IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). Website: <http://www.iba-worldwide.com>

Contact

IBA

Paul-Emmanuel Goethals
Director, Corporate Business Development
& Investor Relations
Phone: +32 10 47 58 16
paul-emmanuel.goethals@iba-group.com